Feature The Truest Test
Over the past few years, there has been a surge in studies that intentionally infect volunteers with a wide variety of pathogens to test novel drugs and vaccines. The so-called "human challenge model" has a long and checkered past that began with 18th century experiments by smallpox vaccine developer Edward Jenner and later fell under intense scrutiny when they were conducted by Nazi doctors, military researchers, and academic scientists working with prisoners. Today, challenge experiments follow strict ethical guidelines, minimize risks to volunteers at every turn, and face increased scrutiny from regulatory agencies. The list of diseases being studied includes malaria, influenza, shigella, dengue, norovirus, tuberculosis, rhinovirus, Escherichia coli, typhoid, giardia, and campylobacter. And scientists who conduct human challenge studies, which typically involve a few dozen participants, say they have critical benefits: In addition to saving time and money, they can reveal harm caused by a potential drug or vaccine before it enters large-scale human efficacy trials. Author: Jon Cohen
CONCLUSIONS: This study does not support exposure of C. jejuni or C. concisus infection as a causal trigger in subsequent development of IBD, since culture-negative patients had similar risk for IBD on long term follow-up. Additional studies including C. concisus exposures for an evaluation of the specific risk of IBD are needed. PMID: 30905214 [PubMed - as supplied by publisher]
Authors: Martini M, Mahroum N, Luigi Bragazzi N, Parodi A PMID: 30905113 [PubMed - in process]
Condition: Influenza Intervention: Biological: Quadrivalent inactivated influenza vaccine (IIV) Sponsors: Stanford University; National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Condition: Multiple Sclerosis Interventions: Drug: Bacille Calmette-Guerin vaccine; Drug: Placebo Sponsor: S. Andrea Hospital Not yet recruiting
Condition: HPV-Related Cervical Carcinoma Intervention: Behavioral: knowledge questioannaire Sponsor: University Hospital, Geneva Not yet recruiting
Condition: Human Papillomavirus Infection Intervention: Other: VACs Sponsors: University of North Carolina, Chapel Hill; Centers for Disease Control and Prevention; American Cancer Society, Inc.; Wisconsin Department of Health and Family Services; New York State Department of Health; Association of Immunization Managers Recruiting
PLYMOUTH MEETING, Pa., March 25, 2019 -- (Healthcare Sales &Marketing Network) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career la... Biopharmaceuticals, Oncology, Personnel Inovio Pharmaceuticals, immunotherapy, cancer vaccine
[Daily Maverick] While many politicians, world leaders and big corporations speak about the future effects of climate change, poor and impoverished nations are already struggling to battle the consequences of rising global temperatures.
The words of YSPH Professor Luke Davis ’s high school teacher still resonate with him as he continues to take on new challenges in diagnosing tuberculosis.
[Gra ça Machel Trust] The Graça Machel Trust, (GMT), the Nelson Mandela Children's Fund, (NMCF) and the Foundation for Community Development (FDC) are greatly concerned about the unfolding effects of Cyclone Idai across parts of Malawi, Mozambique and Zimbabwe. The increasing death toll and numbers of women and children uncounted for is extremely worrisome. The devastation has left communities homeless, unsafe, without food, emergency healthcare and other essential services.